These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30466778)

  • 1. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
    Simon N; Azorin JM
    Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
    Tuplin EW; Holahan MR
    Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
    Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
    Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
    Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
    J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine partial agonists: a new class of antipsychotic.
    Lieberman JA
    CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of modified electroconvulsive therapy and long-acting injectable aripiprazole for dopamine supersensitivity psychosis: a case report.
    Matsuzaka Y; Noguchi M; Kanamura S; Maeda K; Hisano T; Tanaka D; Ando Y; Yamamoto T; Morimoto Y; Ozawa H; Otsuka T
    Neurocase; 2022 Jun; 28(3):310-313. PubMed ID: 35993136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole.
    Prommer E
    Am J Hosp Palliat Care; 2017 Mar; 34(2):180-185. PubMed ID: 26589880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
    Hirose T; Kikuchi T
    J Med Invest; 2005 Nov; 52 Suppl():284-90. PubMed ID: 16366516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do dopamine partial agonists have partial efficacy as antipsychotics?
    Stahl SM
    CNS Spectr; 2008 Apr; 13(4):279-82. PubMed ID: 18408646
    [No Abstract]   [Full Text] [Related]  

  • 14. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
    Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
    Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task.
    Barnes SA; Young JW; Markou A; Adham N; Gyertyán I; Kiss B
    Psychopharmacology (Berl); 2018 May; 235(5):1403-1414. PubMed ID: 29473089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
    Seeman P
    CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
    Inoue A; Nakata Y
    Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.